These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 18356605)

  • 1. The cost-effectiveness of cotrimoxazole prophylaxis in HIV-infected children in Zambia.
    Ryan M; Griffin S; Chitah B; Walker AS; Mulenga V; Kalolo D; Hawkins N; Merry C; Barry MG; Chintu C; Sculpher MJ; Gibb DM
    AIDS; 2008 Mar; 22(6):749-57. PubMed ID: 18356605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Opportunities for improving the efficiency of paediatric HIV treatment programmes.
    Revill PA; Walker S; Mabugu T; Nathoo KJ; Mugyenyi P; Kekitinwa A; Munderi P; Bwakura-Dangarembizi M; Musiime V; Bakeera-Kitaka S; Nahirya-Ntege P; Walker AS; Sculpher MJ; Gibb DM
    AIDS; 2015 Jan; 29(2):201-10. PubMed ID: 25396263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of cotrimoxazole prophylaxis among persons with HIV in Uganda.
    Pitter C; Kahn JG; Marseille E; Lule JR; McFarland DA; Ekwaru JP; Bunnell R; Coutinho A; Mermin J
    J Acquir Immune Defic Syndr; 2007 Mar; 44(3):336-43. PubMed ID: 17327758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of daily cotrimoxazole prophylaxis and antiretroviral therapy on mortality and hospital admissions in HIV-infected Zambian children.
    Walker AS; Mulenga V; Ford D; Kabamba D; Sinyinza F; Kankasa C; Chintu C; Gibb DM;
    Clin Infect Dis; 2007 May; 44(10):1361-7. PubMed ID: 17443476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost and cost-effectiveness of a universal HIV testing and treatment intervention in Zambia and South Africa: evidence and projections from the HPTN 071 (PopART) trial.
    Thomas R; Probert WJM; Sauter R; Mwenge L; Singh S; Kanema S; Vanqa N; Harper A; Burger R; Cori A; Pickles M; Bell-Mandla N; Yang B; Bwalya J; Phiri M; Shanaube K; Floyd S; Donnell D; Bock P; Ayles H; Fidler S; Hayes RJ; Fraser C; Hauck K;
    Lancet Glob Health; 2021 May; 9(5):e668-e680. PubMed ID: 33721566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models.
    Eaton JW; Menzies NA; Stover J; Cambiano V; Chindelevitch L; Cori A; Hontelez JA; Humair S; Kerr CC; Klein DJ; Mishra S; Mitchell KM; Nichols BE; Vickerman P; Bakker R; Bärnighausen T; Bershteyn A; Bloom DE; Boily MC; Chang ST; Cohen T; Dodd PJ; Fraser C; Gopalappa C; Lundgren J; Martin NK; Mikkelsen E; Mountain E; Pham QD; Pickles M; Phillips A; Platt L; Pretorius C; Prudden HJ; Salomon JA; van de Vijver DA; de Vlas SJ; Wagner BG; White RG; Wilson DP; Zhang L; Blandford J; Meyer-Rath G; Remme M; Revill P; Sangrujee N; Terris-Prestholt F; Doherty M; Shaffer N; Easterbrook PJ; Hirnschall G; Hallett TB
    Lancet Glob Health; 2014 Jan; 2(1):e23-34. PubMed ID: 25104632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of cotrimoxazole on causes of death, hospital admissions and antibiotic use in HIV-infected children.
    Mulenga V; Ford D; Walker AS; Mwenya D; Mwansa J; Sinyinza F; Lishimpi K; Nunn A; Gillespie S; Zumla A; Chintu C; Gibb DM;
    AIDS; 2007 Jan; 21(1):77-84. PubMed ID: 17148971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cotrimoxazole prophylaxis for opportunistic infections in children with HIV infection.
    Grimwade K; Swingler GH
    Cochrane Database Syst Rev; 2006 Jan; 2006(1):CD003508. PubMed ID: 16437457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cost-effectiveness of preventing AIDS-related opportunistic infections.
    Freedberg KA; Scharfstein JA; Seage GR; Losina E; Weinstein MC; Craven DE; Paltiel AD
    JAMA; 1998 Jan; 279(2):130-6. PubMed ID: 9440663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of improved treatment services for sexually transmitted diseases in preventing HIV-1 infection in Mwanza Region, Tanzania.
    Gilson L; Mkanje R; Grosskurth H; Mosha F; Picard J; Gavyole A; Todd J; Mayaud P; Swai R; Fransen L; Mabey D; Mills A; Hayes R
    Lancet; 1997 Dec 20-27; 350(9094):1805-9. PubMed ID: 9428251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduction in preterm delivery and neonatal mortality after the introduction of antenatal cotrimoxazole prophylaxis among HIV-infected women with low CD4 cell counts.
    Walter J; Mwiya M; Scott N; Kasonde P; Sinkala M; Kankasa C; Kauchali S; Aldrovandi GM; Thea DM; Kuhn L
    J Infect Dis; 2006 Dec; 194(11):1510-8. PubMed ID: 17083035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of primary prophylaxis of AIDS associated cryptococcosis in Cambodia.
    Micol R; Tajahmady A; Lortholary O; Balkan S; Quillet C; Dousset JP; Chanroeun H; Madec Y; Fontanet A; Yazdanpanah Y
    PLoS One; 2010 Nov; 5(11):e13856. PubMed ID: 21085478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cost effectiveness of home-based provision of antiretroviral therapy in rural Uganda.
    Marseille E; Kahn JG; Pitter C; Bunnell R; Epalatai W; Jawe E; Were W; Mermin J
    Appl Health Econ Health Policy; 2009; 7(4):229-43. PubMed ID: 19905037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
    Shepherd J; Jones J; Takeda A; Davidson P; Price A
    Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of interventions for HIV/AIDS, malaria, syphilis, and tuberculosis in 128 countries: a meta-regression analysis.
    Silke F; Earl L; Hsu J; Janko MM; Joffe J; Memetova A; Michael D; Zheng P; Aravkin A; Murray CJL; Weaver MR
    Lancet Glob Health; 2024 Jul; 12(7):e1159-e1173. PubMed ID: 38876762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Benefits of HIV screening of blood transfusions in Zambia.
    Foster S; Buvé A
    Lancet; 1995 Jul; 346(8969):225-7. PubMed ID: 7616804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cost-effectiveness of prophylaxis strategies for individuals with advanced HIV starting treatment in Africa.
    Walker SM; Cox E; Revill P; Musiime V; Bwakura-Dangarembizi M; Mallewa J; Cheruiyot P; Maitland K; Ford N; Gibb DM; Walker AS; Soares M;
    J Int AIDS Soc; 2020 Mar; 23(3):e25469. PubMed ID: 32219991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluating the costs of cholera illness and cost-effectiveness of a single dose oral vaccination campaign in Lusaka, Zambia.
    Tembo T; Simuyandi M; Chiyenu K; Sharma A; Chilyabanyama ON; Mbwili-Muleya C; Mazaba ML; Chilengi R
    PLoS One; 2019; 14(5):e0215972. PubMed ID: 31150406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of HIV treatment in resource-poor settings--the case of Côte d'Ivoire.
    Goldie SJ; Yazdanpanah Y; Losina E; Weinstein MC; Anglaret X; Walensky RP; Hsu HE; Kimmel A; Holmes C; Kaplan JE; Freedberg KA
    N Engl J Med; 2006 Sep; 355(11):1141-53. PubMed ID: 16971720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Scaling up integrated prevention campaigns for global health: costs and cost-effectiveness in 70 countries.
    Marseille E; Jiwani A; Raut A; Verguet S; Walson J; Kahn JG
    BMJ Open; 2014 Jun; 4(6):e003987. PubMed ID: 24969782
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.